Phase II study of low-dose cyclophosphamide and ipilimumab in metastatic melanoma.

e20025 Background: Ipilimumab (Ipi) has improved clinical outcomes in metastatic melanoma (MM). Previous data suggested that low doses of cyclophosphamide (ldCTX) may have immunomodulatory effects ...